Quantcast
Last updated on April 16, 2014 at 14:08 EDT

Latest Angiopoietin Stories

2013-06-12 08:29:39

Study Meets Primary Endpoint of Progression-Free Survival THOUSAND OAKS, Calif., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 TRINOVA-1 trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS). A statistically significant difference was observed in PFS with a 34 percent reduction in the risk of disease progression or death (HR = 0.66, 95...

2010-01-11 16:45:15

A new method of blocking the genesis of blood vessels that feed tumors may start with the nuclear receptor COUP-TFII (chicken ovalbumin upstream promoter-transcription factor II), said a pair of Baylor College of Medicine (www.bcm.edu) researchers who have studied the factor for more than 20 years. In a report that went online today in the Proceedings of the National Academy of Sciences, a team led by Dr. Ming-Jer Tsai (http://www.bcm.edu/mcb/?PMID=7576) and Dr. Sophia Y. Tsai...